{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T05:41:16Z","timestamp":1764481276550,"version":"3.46.0"},"reference-count":9,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2018,3,13]],"date-time":"2018-03-13T00:00:00Z","timestamp":1520899200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Case Reports"],"published-print":{"date-parts":[[2018,5]]},"abstract":"<jats:title>Key Clinical Message<\/jats:title>\n                  <jats:p>Asymptomatic hyperbilirubinemia in a patient with no underlying liver disease or renal impairment while on lenalidomide therapy may be attributable to the unmasking of previously undiagnosed Gilbert's syndrome, as previously shown in the literature. The hyperbilirubinemia should resolve after discontinuation of the drug.<\/jats:p>","DOI":"10.1002\/ccr3.1471","type":"journal-article","created":{"date-parts":[[2018,3,15]],"date-time":"2018-03-15T06:46:01Z","timestamp":1521096361000},"page":"875-877","source":"Crossref","is-referenced-by-count":2,"title":["Hyperbilirubinemia following lenalidomide administration"],"prefix":"10.1002","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1552-5892","authenticated-orcid":false,"given":"Veronica","family":"Azmy","sequence":"first","affiliation":[{"name":"Yale University School of Medicine New Haven CT 06510"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"Neparidze","sequence":"additional","affiliation":[{"name":"Yale University School of Medicine Smilow Cancer Hospital, New Haven CT 06510"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,3,13]]},"reference":[{"key":"e_1_2_4_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-08-303487"},{"key":"e_1_2_4_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70284-0"},{"key":"e_1_2_4_4_1","unstructured":"Revlimid [package insert].Summit NJ:Celgene Corporation;2013."},{"key":"e_1_2_4_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-097758"},{"key":"e_1_2_4_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0b013e3182603598"},{"key":"e_1_2_4_7_1","doi-asserted-by":"crossref","first-page":"5317","DOI":"10.1182\/blood.V126.23.5317.5317","article-title":"Thrombotic microangiopathy in multiple myeloma","volume":"126","author":"Yui J.","year":"2015","journal-title":"Blood"},{"key":"e_1_2_4_8_1","doi-asserted-by":"publisher","DOI":"10.1177\/1078155212439492"},{"key":"e_1_2_4_9_1","doi-asserted-by":"publisher","DOI":"10.1159\/000326935"},{"key":"e_1_2_4_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/pr.2015.247"}],"container-title":["Clinical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fccr3.1471","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ccr3.1471","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T05:37:22Z","timestamp":1764481042000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ccr3.1471"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,13]]},"references-count":9,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["10.1002\/ccr3.1471"],"URL":"https:\/\/doi.org\/10.1002\/ccr3.1471","archive":["Portico"],"relation":{},"ISSN":["2050-0904","2050-0904"],"issn-type":[{"type":"print","value":"2050-0904"},{"type":"electronic","value":"2050-0904"}],"subject":[],"published":{"date-parts":[[2018,3,13]]}}}